- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Lurbinectedin, Durvalumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
- Interventions
- Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride, Lurbinectedin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more
- Conditions
- Ovarian Cancer
- Interventions
- Paclitaxel, Bevacizumab, Lurbinectedin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- PM01183
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Lurbinectedin, Palliative Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Lung Cancer, Small-cell Lung Cancer
- Interventions
- Trilaciclib, Lurbinectedin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Chapel Hill, North Carolina
- Conditions
- Gastrointestinal Malignancies
- Interventions
- Lurbinectedin 4 MG Injection [Zepzelca]
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 30
- States / cities
- Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Durvalumab, Lurbinectedin
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Solid Tumors
- Interventions
- lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- Up to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- lurbinectedin (PM01183)
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Aurora, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Small-cell Lung Cancer
- Interventions
- Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX), Vincristine (VCR), Topotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Fullerton, California + 26 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 17
- States / cities
- Stanford, California • Norwich, Connecticut • Fort Myers, Florida + 14 more
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Zepzelca
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Norwich, Connecticut • Brooksville, Florida + 29 more
- Conditions
- Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Advanced Soft-tissue Sarcoma
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- ERLINDA M GORDON
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Lurbinectedin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Kissimmee, Florida • Tampa, Florida
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706, Topotecan, Lurbinectedin, Amrubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more
- Conditions
- Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
- Interventions
- PM01183 + paclitaxel +/- bevacizumab
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Stenoparib/Temozolomide, Lurbinectedin
- Combination Product · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- SCLC, Small Cell Cancer, Advanced Solid Tumor, High Grade Neuroendocrine Cancers
- Interventions
- Lurbinectedin, Berzosertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
- Interventions
- Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel, Docetaxel, Gemcitabine, Etoposide, Irinotecan, Topotecan, Lurbinectedin
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania